PedAM
Pediatric Disease Annotations & Medicines
| Disease | vascular disease |
| Phenotype | |type 2 diabetes |
| Sentences | 223 |
| PubMedID- 24199160 | In the phase ii effect of the dual peroxisome proliferator-activated receptor-α/γagonist aleglitazar on risk of cardiovascular disease in patients with type 2 diabetes (synchrony) study, aleglitazar showed dose-dependent metabolic benefits, including significant dose-dependent reduction in hba1c of -0.36% (4 mmol/mol, 50 µg; p=0.048) to -1.35% (15 mmol/mol, 600 µg; p<0.0001) in 16 weeks of treatment compared to placebo. |
| PubMedID- 20929988 | With the heightened risk of cardiovascular disease in type 2 diabetes, aggressive cardiovascular risk-factor management is recommended (8). |
| PubMedID- 25923078 | type 2 diabetes mellitus patients with cardiovascular disease showed higher expression of plasma retinol binding protein and glutathione peroxidase-3 compared to those without cardiovascular disease and non-diabetic controls. |
| PubMedID- 20700576 | Oral disease and subsequent cardiovascular disease in people with type 2 diabetes: a prospective cohort study based on the action in diabetes and vascular disease: preterax and diamicron modified-release controlled evaluation (advance) trial. |
| PubMedID- 23990951 | However, fasting hyperglycaemia was not found to be predictive of the incidence of cardiovascular disease in patients with type 2 diabetes. |
| PubMedID- 21517955 | Post-meal hyperglycaemia is considered a risk factor for cardiovascular disease in patients with type 2 diabetes [1]. |
| PubMedID- 22718811 | Statins and beyond: concurrent strategies for prevention of cardiovascular disease in patients with type 2 diabetes. |
| PubMedID- 23908805 | Archived serum samples from the heart outcomes prevention evaluation (hope) study were analyzed for hp genotype and correlated with the occurrence of non-fatal myocardial infarction (mi), stroke, and cardiovascular disease (cvd) death in patients with type 2 diabetes. |
| PubMedID- 22919466 | However, many population-based association studies between abi distribution and cardiovascular diseases in type 2 diabetes have been carried out in western countries, whereas, no such epidemiological data are available in north indian subjects with type 2 diabetes mellitus till date according to the information gathered from pubmed. |
| PubMedID- 22285702 | Risk of elevated resting heart rate on the development of type 2 diabetes in patients with clinically manifest vascular diseases. |
| PubMedID- 25847351 | Recent epidemiological evidence has also shown a direct association between cognitive decline and markers of symptomatic and asymptomatic vascular disease in people with type 2 diabetes [5]. |
| PubMedID- 23323191 | The pathophysiology underlying cognitive change in type 2 diabetes is examined with reference to vascular disease, hypoglycaemia, inflammation and insulin levels. |
| PubMedID- 25149070 | Favourable effects of fenofibrate on lipids and cardiovascular disease in women with type 2 diabetes: results from the fenofibrate intervention and event lowering in diabetes (field) study. |
| PubMedID- 19918016 | The value of low-dose aspirin as primary prevention for cardiovascular disease (cvd) in patients with type 2 diabetes remains to be established. |
| PubMedID- 21763654 | Conclusions: this review highlights the association between micro- and macrovascular disease in type 2 diabetes, underlining the importance of early detection of microangiopathy for vascular risk assessment in type 2 diabetes. |
| PubMedID- 21949229 | vascular disease in type 2 diabetes affects all arterial beds, with insulin resistance present throughout the continuum of cvd, from the earliest stages through left ventricular dysfunction to the syndrome of heart failure, with diabetes particularly detrimental in changing this phenotype. |
| PubMedID- 23900314 | Objectives: to provide a systematic and quantitative summary of the association between severe hypoglycaemia and risk of cardiovascular disease in people with type 2 diabetes and to examine the sensitivity of the association to possible uncontrolled confounding by unmeasured comorbid severe illness using a bias analysis. |
| PubMedID- 25256018 | Aims: this study aimed to investigate the impact of early-onset diabetes on the risk of microvascular diseases in chinese with type 2 diabetes mellitus (t2dm). |
| PubMedID- 24278703 | Finally, the results of the accord trial showed that the combination of fenofibrate and simvastatin does not reduce the risk of cardiovascular disease in patients with type 2 diabetes mellitus, as compared with statin monotherapy [78]; only subgroups of patients with dyslipidemia seem to benefit from fibrate therapy. |
| PubMedID- 24855344 | Several large-scale, prospective, randomized trials have documented that lowering glycemic levels can prevent the development of microvascular disease in people with type 2 diabetes mellitus (t2dm). |
| PubMedID- 24379686 | Dyslipidemia, an established risk factor for cardiovascular disease, is common in patients with type 2 diabetes, affecting almost 50% of this population. |
| PubMedID- 24582686 | The ideal blood pressure target to prevent cardiovascular disease in type 2 diabetes: a neutral viewpoint. |
| PubMedID- 25145830 | Relationships between reduced heart rate variability and pre-clinical cardiovascular disease in patients with type 2 diabetes. |
| PubMedID- 25197673 | Objective: to investigate the potential benefits of acarbose treatment on cardiovascular disease (cvd) in patients with type 2 diabetes by using nationwide insurance claim dataset. |
| PubMedID- 20500877 | An inverse association between weight and adiponectin level has been found [22] and low plasma-adiponectin levels are considered to be a predictor of cardiovascular disease in patients with type 2 diabetes [23]. |
| PubMedID- 25815676 | Glucagon-like peptide-1 (glp-1) has been demonstrated to play an important role in type 2 diabetes mellitus, leading to cardiovascular diseases. |
| PubMedID- 21955218 | Thrombin generation in type 2 diabetes with albuminuria and macrovascular disease. |
| PubMedID- 26043186 | Clinical outcome trials evaluating primary cardiovascular disease prevention with aspirin in type 2 diabetes may need to consider using a more frequent dosing schedule. |
| PubMedID- 23967086 | It is worth noting that the field trial [22] and accord lipid study [23] revealed that fibrates reduced nonfatal coronary events in patients at risk for cardiovascular disease, including those with type 2 diabetes. |
| PubMedID- 23872939 | Purpose: elevated postprandial glycemic (ppg) excursions are significant risk factors for cardiovascular disease in type 2 diabetes patients. |
| PubMedID- 23466101 | Objectives: low levels of blood adiponectin contribute to an increased risk of cardiovascular disease (cvd) in patients with type 2 diabetes mellitus (t2dm). |
| PubMedID- 20380625 | type 2 diabetes (t2d) is associated with increased cardiovascular disease and mortality. |
| PubMedID- 25924043 | [prevention of cardiovascular disease in patients with type 2 diabetes]. |
| PubMedID- 24465050 | And, would monotherapy with either or both of those drugs reduce the risk of cardiovascular disease events in patients with type 2 diabetes mellitus? |
| PubMedID- 21346183 | The action to control cardiovascular risk in diabetes (accord) study was a multicenter randomized controlled treatment trial testing independent effects of two strategies of control of blood glucose, blood pressure, and lipids on cardiovascular disease (cvd) in patients with type 2 diabetes (1). |
| PubMedID- 21519250 | Summary: fibrate therapy does not reduce mortality but may reduce nonfatal coronary events in patients at risk for cardiovascular disease, including those with type 2 diabetes. |
| PubMedID- 22440125 | Microalbuminuria is one of the strongest predictors of both adverse renal and cardiovascular disease (cvd) outcomes in patients with type 2 diabetes mellitus. |
| PubMedID- 23166566 | Control of risk factors for cardiovascular disease among adults with previously diagnosed type 2 diabetes mellitus: a descriptive study from a middle eastern arab population. |
| PubMedID- 23166795 | Observational study of the association of first insulin type in uncontrolled type 2 diabetes with macrovascular and microvascular disease. |
| PubMedID- 22340758 | Cardiovascular diseases (cvd) in patients with type 2 diabetes are a large and increasing health problem. |
| PubMedID- 23604419 | The great burden of cardiovascular disease (cvd) in patients with type 2 diabetes is well known. |
| PubMedID- 22081557 | Background: the prevalence of dyslipidaemia and the risk of cardiovascular disease are elevated in patients with type 2 diabetes. |
| PubMedID- 20964737 | Glycemia and cardiovascular diseases in type 2 diabetes. |
| PubMedID- 20705869 | Cardiovascular disease in type 2 diabetes: attributable risk due to modifiable risk factors. |
| PubMedID- 20047560 | Dyslipidaemia contributes to endothelial dysfunction and cvd (cardiovascular disease) in type 2 diabetes mellitus. |
| PubMedID- 21057575 | A prospective cohort study analyzed the relative risk of macrovascular disease in patients with newly diagnosed type 2 diabetes and determined whether an intensive approach to dietary management, besides satisfactory glycemic control, would ameliorate the long-term cardiovascular risk and reduce the incidence of dcm and cardiovascular mortality. |
| PubMedID- 26116592 | Plasma adiponectin levels inversely correlate to clinical parameters in type 2 diabetes mellitus patients with macrovascular diseases. |
| PubMedID- 21700920 | Identifying and removing barriers to physical activity is important because of the strong relationship between physical inactivity and cardiovascular disease in people with type 2 diabetes and the likely cardiovascular benefits for people with type 1 diabetes (5,6). |
| PubMedID- 21398276 | Circulating angiopoietic cells and diabetic retinopathy in type 2 diabetes mellitus, with or without macrovascular disease. |
| PubMedID- 24714221 | Background: although much attention has been focused on the association between chronic hyperglycemia and cerebrovascular diseases in type 2 diabetes mellitus (dm) patients, there is no data regarding the risk of ischemic stroke after a hyperosmolar hyperglycemic state (hhs) attack. |